PENNINGTON, N.J. and
SAN DIEGO, March 25, 2021 /PRNewswire/ -- OncoSec
Medical Incorporated (NASDAQ:ONCS) (the "Company" or "OncoSec"), a
biotechnology company focused on cytokine-based intratumoral cancer
immunotherapies, today announced it will sponsor a key opinion
leader (KOL) webinar to be held by LifeSci Advisors discussing the
anti-PD-1 checkpoint refractory metastatic melanoma landscape and
the impact of the results from ILLUMINATE-301 on Wednesday, March 31, 2021 at 12:00 p.m. ET.
The webinar features presentations by KOLs Gregory Daniels,
M.D., Ph.D., UC San Diego Health, Paolo
Ascierto, M.D., National Tumor Institute Fondazione G.
Pascale, John M. Kirkwood, M.D.,
University of Pittsburgh, and
Matteo Carlino, M.D., Westmead and
Blacktown Hospitals.
A Fireside Chat moderated by Neil
Canavan, author of "The Cure Within," will follow the formal
presentations and the KOLs will be available to answer questions
afterward.
To register for the event, please click here.
The KOLs will discuss the anti-PD-1 checkpoint refractory
metastatic melanoma landscape and commercial outlook:
- Gregory Daniels, M.D.,
Ph.D., UC San Diego Health, will lead the discussion on
tumor-infiltrating lymphocytes (TILs). Dr. Daniels, a
board-certified oncologist, coordinates care for patients with
melanoma, skin cancers and head and neck cancers. Dr. Daniels
treats certain skin cancers with highly effective immunotherapy
approaches. He is part of the Precision Immunotherapy Clinic, which
offers the most promising investigational immunotherapies for many
types of cancer. As a professor in the Department of Medicine, Dr.
Daniels is involved in training medical students, residents and
fellows at UC San Diego School of Medicine. Active in research,
much of his work has focused on understanding the link between
autoimmunity and tumor immunity in developing more effective and
less toxic immune-stimulatory approaches for patients with
melanoma. Dr. Daniels completed his fellowship and residency at
Mayo Clinic in Rochester, Minn.
and earned his medical degree from University
of Southern California Keck School of Medicine.
- Paolo Ascierto, M.D.,
National Tumor Institute Fondazione G. Pascale, will
co-lead the discussion on intratumoral (IT) toll-like receptor
(TLR) 9. Dr. Ascierto is the Director of the Dept. of Melanoma,
Cancer Immunotherapy and Development Therapeutics at the National
Tumor Institute IRCCS Fondazione G. Pascale in Naples, Italy. He previously served as a
postdoctoral fellow and then as vice-director of the Department of
Clinical Immunology. His research interest has focused on diagnosis
and treatment of melanoma, including assessment of new molecular
markers for tumor progression, targeted therapies, immunotherapy
and vaccination treatments. He has served as principal investigator
in numerous clinical trials and has published numerous
peer-reviewed articles on these topics. He earned his M.D. and
received board-certification in oncology from the University of
Naples.
- John M. Kirkwood, M.D.,
University of Pittsburgh, will
co-lead the discussion on intratumoral (IT) toll-like receptor
(TLR) 9. Dr. Kirkwood, M.D. is board-certified in internal medicine
and medical oncology and is Professor of Medicine at the
University of Pittsburgh. He received
his medical degree from Yale University School
of Medicine, where he was also an intern and resident in
internal medicine. His subspecialty is in medical oncology and he
completed his fellowship in this field at the Dana Farber Cancer
Institute and Harvard Medical School.
Dr. Kirkwood's early research in tumor immunology was done at
Memorial Sloan Kettering and his postdoctoral fellowship work in
tumor immunology at Harvard University.
He is a member of the New York Academy of Sciences, the American
Society for Clinical Oncology, the American Association for Cancer
Research, the American Medical Association, the Eastern Cooperative
Oncology Group, the National Cancer Foundation, the International
Society for Interferon and Cytokine Research, the Society for
Immunotherapy of Cancer, the Society for Melanoma Research, the
Clinical Immunology Society and the Society of Natural
Immunity.
- Matteo Carlino, M.D.,
Westmead and Blacktown Hospitals, will lead the discussion
on IT DNA plasmid-based Interleukin-12 (IL-12). Dr. Carlino is a
Medical Oncologist at Westmead and Blacktown Hospitals, where he
leads melanoma clinical trials program, a Clinical associate
professor at The University of Sydney
and a Faculty Member at MIA. He undertook a Ph.D. examining
predictors of response and mechanisms of resistance to BRAF and MEK
inhibitor treated melanoma. Dr. Carlino continues to be involved in
the translational research program based at MIA and the Westmead
Institute for Cancer Research. He is an investigator on multiple
Phase I, II and III clinical trials in melanoma targeted and
immunotherapy.
About OncoSec Medical Incorporated
OncoSec Medical
Incorporated (the "Company," "OncoSec," "we" or "our") is a
late-stage biotechnology company focused on developing
cytokine-based intratumoral immunotherapies to stimulate the body's
immune system to target and attack cancer. OncoSec's lead
immunotherapy investigational product candidate – TAVO™
(tavokinogene telseplasmid) – enables the intratumoral delivery of
DNA-based interleukin-12 (IL-12), a naturally occurring protein
with immune-stimulating functions. The technology, which employs
electroporation, is designed to produce a controlled, localized
expression of IL-12 in the tumor microenvironment, enabling the
immune system to target and attack tumors throughout the body.
OncoSec has built a deep and diverse clinical pipeline utilizing
TAVO™ as a potential treatment for multiple cancer indications
either as a monotherapy or in combination with leading checkpoint
inhibitors; with the latter potentially enabling OncoSec to address
a great unmet medical need in oncology: anti-PD-1 non-responders.
Results from recently completed clinical studies of TAVO™ have
demonstrated a local immune response, and subsequently, a systemic
effect as either a monotherapy or combination treatment approach
along with an acceptable safety profile, warranting further
development. In addition to TAVO™, OncoSec is identifying and
developing new DNA-encoded therapeutic candidates and tumor
indications for use with its new Visceral Lesion Applicator (VLA),
to target deep visceral lesions, such as liver, lung or pancreatic
lesions. For more information, please visit www.oncosec.com.
TAVO™ is a trademark of OncoSec Medical Incorporated.
Risk Factors and Forward-Looking Statements
This
release, as well as other information provided from time to time by
the Company or its employees, may contain forward-looking
statements that involve a number of risks and uncertainties that
could cause actual results to differ materially from those
anticipated in the forward-looking statements. Forward-looking
statements provide the Company's current beliefs, expectations and
intentions regarding future events and involve risks, uncertainties
(some of which are beyond the Company's control) and assumptions.
For those statements, we claim the protection of the safe harbor
for forward-looking statements contained in the Private Securities
Litigation Reform Act of 1995. You can identify forward-looking
statements by the fact that they do not relate strictly to
historical or current facts. These statements may include words
such as "anticipate," "believe," "could," "estimate," "expect,"
"intend," "may," "plan," "potential," "should," "will" and "would"
and similar expressions (including the negative of these terms).
Although we believe that expectations reflected in the forward-
looking statements are reasonable, we cannot guarantee future
results, levels of activity, performance or achievements. The
Company intends these forward-looking statements to speak only at
the time they are published on or as otherwise specified, and does
not undertake to update or revise these statements as more
information becomes available, except as required under federal
securities laws and the rules and regulations of the Securities
Exchange Commission ("SEC"). In particular, you should be aware
that the success and timing of our clinical trials, including
safety and efficacy of our product candidates, patient accrual,
unexpected or expected safety events, the impact of COVID-19 on the
supply of our candidates or the initiation or completion of
clinical trials and the usability of data generated from our trials
may differ and may not meet our estimated timelines. Please refer
to the risk factors and other cautionary statements provided in the
Company's Annual Report on Form 10-K for the fiscal year ended
July 31, 2019 and subsequent periodic
and current reports filed with the SEC (each of which can be found
at the SEC's website www.sec.gov), as well as other factors
described from time to time in the Company's filings with the
SEC.
Company Contact
Brian
Leuthner
Chief Operating Officer
investors@oncosec.com
Media Contact
Patrick
Bursey
LifeSci Communications
+1-646-970-4688
pbursey@lifescicomms.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/oncosec-medical-sponsoring-kol-webinar-on-a-high-unmet-medical-need-anti-pd-1-checkpoint-refractory-metastatic-melanoma-301256004.html
SOURCE OncoSec Medical Incorporated
